1. Metformin use and the risk of anal intraepithelial neoplasia in type II diabetic patients
- Author
-
Ya Ching Hung, Joshua H. Wolf, Arun A. Mavanur, Angela Ting-Wei Hsu, Christopher R. D'Adamo, Sandy H. Fang, and Shane Svoboda
- Subjects
medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Papillomavirus Infections ,Gastroenterology ,food and beverages ,Type 2 Diabetes Mellitus ,Anal dysplasia ,Anus Neoplasms ,Logistic regression ,medicine.disease ,Metformin ,Diabetes Mellitus, Type 2 ,Case-Control Studies ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Anal cancer ,Prospective Studies ,Prospective cohort study ,business ,Carcinoma in Situ ,medicine.drug - Abstract
AIM Emerging evidence has suggested that metformin may be protective against the development of human-papillomavirus-related cancers. Anal intraepithelial neoplasia (AIN) is highly associated with human papillomavirus infection and a precancerous status of anal cancer. The aim of this study was to investigate the relationship between metformin usage and the development of AIN in a large national sample. METHODOLOGY The IBM MarketScan dataset was used to design a nested case-control study from 2010 to 2017. Patients aged 18-65 years with type 2 diabetes mellitus (DM) were evaluated, and cases of AIN were identified. Four controls were randomly selected in the risk set of each case by using incidence density sampling. The association between metformin usage and AIN was assessed using multivariate logistic regression modelling. RESULTS A total of 258 patients with type 2 DM were diagnosed with AIN during the study interval, and these were matched to 1032 control patients without a diagnosis of AIN. Patients who developed AIN had 38% lower odds of prior metformin use compared to those without a history of AIN (P
- Published
- 2021
- Full Text
- View/download PDF